Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
RSC Medicinal Chemistry|September 12, 2022
Recent applications of covalent chemistries in protein-protein interaction inhibitorsAlexandria M Chan, Christopher C Goodis, Elie G Pommier, et al.RSC Medicinal Chemistry|February 10, 2023
Discovery of <i>N</i>-sulfonylated aminosalicylic acids as dual MCL-1/BCL-xL inhibitorsLijia Chen, Jay Chauhan, Jeremy L Yap, et al.Drug Development Research|May 15, 2025
Augmenting the Anti-Leukemic Activity of the BCL-2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL-2/HDAC1 and Dual BCL-2/HDAC6 InhibitorsAlexandria M Chan, Christian Eberly, Brandon Drennen, et al.ACS Pharmacology & Translational Science|November 21, 2022
Modified Suberoylanilide Hydroxamic Acid Reduced Drug-Associated Immune Cell Death and Organ Damage under Lipopolysaccharide Inflammatory ChallengeNhu Truong, Christopher C Goodis, Andrea L Cottingham, et al.European Journal of Medicinal Chemistry|January 15, 2025
The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitorsChristopher C Goodis, Christian Eberly, Alexandria M Chan, et al.RSC Medicinal Chemistry|September 12, 2022
Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leadsBrandon Drennen, Christopher C Goodis, Nathan Bowen, et al.Bioengineering & Translational Medicine|January 9, 2024
Multimodal nanoparticle-containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammationNhu Truong, Andrea L Cottingham, Shruti Dharmaraj, et al.Pageof 1